An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer

Guian Zhang,1 Yong Luo2 1School of Medicine, South China University of Technology, Guangzhou, 510006, People’s Republic of China; 2Department of Urology, the Second People’s Hospital of Foshan, Affiliated Foshan Hospital of Southern Medical University, Foshan, 528000, People’s Republic of ChinaCorre...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhang G, Luo Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	prostate cancer lncrna biochemical recurrence tmb immune landscape medical treatment. Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c1b9ff2d73b140fab8d844a993e271e9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c1b9ff2d73b140fab8d844a993e271e9
record_format	dspace
spelling	oai:doaj.org-article:c1b9ff2d73b140fab8d844a993e271e92021-11-30T18:50:36ZAn Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer1178-7074https://doaj.org/article/c1b9ff2d73b140fab8d844a993e271e92021-11-01T00:00:00Zhttps://www.dovepress.com/an-immune-related-lncrna-signature-to-predict-the-biochemical-recurren-peer-reviewed-fulltext-article-IJGMhttps://doaj.org/toc/1178-7074Guian Zhang,1 Yong Luo2 1School of Medicine, South China University of Technology, Guangzhou, 510006, People’s Republic of China; 2Department of Urology, the Second People’s Hospital of Foshan, Affiliated Foshan Hospital of Southern Medical University, Foshan, 528000, People’s Republic of ChinaCorrespondence: Yong LuoDepartment of Urology, the Second People’s Hospital of Foshan, Affiliated Foshan Hospital of Southern Medical University, 78 Weiguo Road, Foshan, 528000, People’s Republic of ChinaTel +86-15625093895Fax +86-0757-88032009Email luomou5@outlook.comPurpose: This study aims to construct an immune-related signature to provide comprehensive insights into the immune landscape of prostate cancer, which can predict biochemical recurrence (BCR) and clinical treatment.Methods: Based on The Cancer Genome Atlas (TCGA) dataset, a signature constructed by DEirlncRNAs pairs was determined. The receiver operating characteristic curve analysis, Kaplan–Meier analysis, nomogram, and decision curve analysis were used to analyze it. Then, immunophenoscore (IPS), immune cell infiltration, tumor mutation burden (TMB), and immune function were investigated. Finally, we evaluated the role of the signature in medical treatment.Results: A signature constructed by 10 valid DEirlncRNAs pairs was identified in the training set and validated well in the testing and entire set. The signature was a reliable and independent prognostic indicator to predict the BCR of prostate cancer, which was better than the clinicopathological characteristics. After dividing the patients into low- and high-risk groups by median value, we found that the high-risk group had shorter BCR-free time and higher TMB levels. Furthermore, the high-risk group was negatively associated with plasma B cells and CD+8 T cells. IPS and immune functions, such as immune checkpoints and human leukocyte antigen, were significantly different between the two groups. Low-risk group was more sensitive to endocrine therapy and immunotherapy, while high-risk group was more inclined to targeted drugs. Both groups had their own sensitive chemotherapy.Conclusion: We established a novel signature to predict BCR and validated its role in the immune landscape of prostate cancer, which could help patients receive personalized medical treatment.Keywords: prostate cancer, lncRNA, biochemical recurrence, TMB, immune landscape, medical treatmentZhang GLuo YDove Medical Pressarticleprostate cancerlncrnabiochemical recurrencetmbimmune landscapemedical treatment.Medicine (General)R5-920ENInternational Journal of General Medicine, Vol Volume 14, Pp 9031-9049 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	prostate cancer lncrna biochemical recurrence tmb immune landscape medical treatment. Medicine (General) R5-920
spellingShingle	prostate cancer lncrna biochemical recurrence tmb immune landscape medical treatment. Medicine (General) R5-920 Zhang G Luo Y An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer
description	Guian Zhang,1 Yong Luo2 1School of Medicine, South China University of Technology, Guangzhou, 510006, People’s Republic of China; 2Department of Urology, the Second People’s Hospital of Foshan, Affiliated Foshan Hospital of Southern Medical University, Foshan, 528000, People’s Republic of ChinaCorrespondence: Yong LuoDepartment of Urology, the Second People’s Hospital of Foshan, Affiliated Foshan Hospital of Southern Medical University, 78 Weiguo Road, Foshan, 528000, People’s Republic of ChinaTel +86-15625093895Fax +86-0757-88032009Email luomou5@outlook.comPurpose: This study aims to construct an immune-related signature to provide comprehensive insights into the immune landscape of prostate cancer, which can predict biochemical recurrence (BCR) and clinical treatment.Methods: Based on The Cancer Genome Atlas (TCGA) dataset, a signature constructed by DEirlncRNAs pairs was determined. The receiver operating characteristic curve analysis, Kaplan–Meier analysis, nomogram, and decision curve analysis were used to analyze it. Then, immunophenoscore (IPS), immune cell infiltration, tumor mutation burden (TMB), and immune function were investigated. Finally, we evaluated the role of the signature in medical treatment.Results: A signature constructed by 10 valid DEirlncRNAs pairs was identified in the training set and validated well in the testing and entire set. The signature was a reliable and independent prognostic indicator to predict the BCR of prostate cancer, which was better than the clinicopathological characteristics. After dividing the patients into low- and high-risk groups by median value, we found that the high-risk group had shorter BCR-free time and higher TMB levels. Furthermore, the high-risk group was negatively associated with plasma B cells and CD+8 T cells. IPS and immune functions, such as immune checkpoints and human leukocyte antigen, were significantly different between the two groups. Low-risk group was more sensitive to endocrine therapy and immunotherapy, while high-risk group was more inclined to targeted drugs. Both groups had their own sensitive chemotherapy.Conclusion: We established a novel signature to predict BCR and validated its role in the immune landscape of prostate cancer, which could help patients receive personalized medical treatment.Keywords: prostate cancer, lncRNA, biochemical recurrence, TMB, immune landscape, medical treatment
format	article
author	Zhang G Luo Y
author_facet	Zhang G Luo Y
author_sort	Zhang G
title	An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer
title_short	An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer
title_full	An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer
title_fullStr	An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer
title_full_unstemmed	An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer
title_sort	immune-related lncrna signature to predict the biochemical recurrence and immune landscape in prostate cancer
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/c1b9ff2d73b140fab8d844a993e271e9
work_keys_str_mv	AT zhangg animmunerelatedlncrnasignaturetopredictthebiochemicalrecurrenceandimmunelandscapeinprostatecancer AT luoy animmunerelatedlncrnasignaturetopredictthebiochemicalrecurrenceandimmunelandscapeinprostatecancer AT zhangg immunerelatedlncrnasignaturetopredictthebiochemicalrecurrenceandimmunelandscapeinprostatecancer AT luoy immunerelatedlncrnasignaturetopredictthebiochemicalrecurrenceandimmunelandscapeinprostatecancer
_version_	1718406349439631360

An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer

Ejemplares similares